charts have no meaning. its like analyzing bunch of random data. the only thing that moves a stock and increases/decreases its market cap is useful information and not random day to day stock movement. I've never seen a chartiest who didn't talk from both side his mouth.
Here's the bottom line: ABBV should be the company taking the enormous hit, not ENTA. Instead of getting 3-4 billion in revenues, now it might be 1-2 billion. But ABBV will get at least that, because they will start a price war with GILD, which has their drug priced at $84,000. ABBV will come in substantially below that, and insurance companies don't care that you need to take 4 pills instead of 1 - the cure rate is the same. So if ABBV gets 2 bill, then ENTA will get about 300 mill, with no value on the rest of their pipeline. So I think the price is going to drift back into the $33 range, and will get back up to $35-$38 after approvals. Remember, they got breakthrough designation so there shouldn't be any holdups getting the drug approved.